Secundum quidam Jabbar et al. De Gothenburg in University of Sweden, targeted modo mole Espectrometría secundum tribus ex biomarkers CYSTA identify expriment et decernant, fluidi potest verius highly facultatem pancreaticum in developing anorum pancreaticum cancer, . Alium ducatum seu confirmare valeat experimentalem methodus studiorum auxilium cancer diagnosis temporis intercessit ne tincidunt arcu. (J Oncol Clin. Poema Online November XXII, MMXVII)
Cystic lesions of the pancreas are very common in imaging, and about half are pancreaticum cancer, lesions. Therefore, accurate and specific diagnosis is essential for the correct treatment of patients. Unfortunately, the currently used diagnostic methods cannot effectively distinguish between pancreatic precancerous lesions and malignant pancreatic cystic lesions.
Inquisitores uti liquor et cystici nactus per exempla diutius tolerantem conventional ultrasound endoscopy et analysis sub ductu eiusdem servet. In qua pulsa, cohors studiis XXIV aegris, in exploratory dapibus biology modum identified quod non providere notitia in VIII candidatus biomarkers malignorum transmutatio DYSPLASIA et summus gradu / carcinomati similis mutationes. Varia deinceps et quantitatis analysis de XXX magna mole Espectrometría reactionem parallel intitulatum peptides et factae sunt super LXXX aegris in notitia paro quod LXVIII in aegris verificationem paro. In finem in puncto, vel orci diagnosis de morbis corporis studium fuit effectus sequantur, est.
The results show that the best markers for malignant tumors may be a group of peptides derived from MUC-5AC and MUC-2. These markers can identify precancerous lesions / malignant lesions from benign lesions. The accuracy is as high as 97%. Compared with the cystic liquid carcinoembryonic antigen and cytological detection of these standard identification methods, the accuracy of these standard methods is 61% (95% CI 46% ~ 74%, P <0.001) and 84% (95% CI 71% ~ 92%, P = 0.02). MUC-5AC combined with prostate stem cell antigen can identify high-grade dysplasia or cancer, with an accuracy of 96%, can detect 95% of malignant lesions or severe dysplasia, and the detection rate of carcinoembryonic antigen and cytology 35% and 50% respectively (P <0.001, P = 0.003).
